This week: Insights into the comparative analysis of COVID and non-COVID pneumonia; how myopathy, with metabolic disturbances and amyloid deposits, is discovered in persons with Long COVID who experience post-exertional malaise; and the Pfizer COVID-19 vaccine is shown to be effective in children and adolescents.
Monthly elebsiran plus tobevibart achieved undetectable HDV RNA with ALT normalization in 44% of patients at week 48 in the pivotal phase 3 ECLIPSE 1 trial.
Charles M. Walworth, MD, of Labcorp discusses a new hepatitis D reflex pathway, internal data showing 8.3% of HBsAg-positive patients screened for HDV, and lessons from hepatitis C reflex testing.
In early in vitro testing, a bacterial cellulose dressing loaded with bacteriophages reduced S aureus and P aeruginosa biofilms, and optimized versions reached 70% to 90% reductions.
PAHO revoked the US measles elimination status this week. Nina Masters, PhD, MPH, offers commentary on the factors leading to it including vaccine hesitancy as well as unintended consequences such as the outbreak-driven spikes in measles titer testing among adults over 50.
Ryan Shields, PharmD, MS, explains how rapid diagnostics, aggressive β-lactam dosing in CRRT, and cefepime-zidebactam fit within the IDSA 2026 guidance on antimicrobial-resistant Gram-negative infections.
The World Health Organization (WHO) confirmed 2 sporadic, camel-linked MERS-CoV infections with both patients recovered and no secondary transmission among 99 traced contacts.